首页 > 最新文献

Regenerative medicine最新文献

英文 中文
CGRP promotes osteogenic differentiation by regulating macrophage M2 polarization through HDAC6/AKAP12 signaling pathway. CGRP 通过 HDAC6/AKAP12 信号通路调节巨噬细胞 M2 极化,从而促进成骨分化。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/17460751.2024.2370697
Wenjing Chen, Lin Ma, Wencai Sun, Wenlong Xiao, Hao Guo, Jiang Xiu, Xin Jiang

Aim: To determine the mechanism of Calcitonin gene-related peptide (CGRP) in bone healing.Materials & methods: Alkaline phosphatase (ALP) activity and inflammatory-factor levels were detected using ELISA. Osteogenic differentiation was assessed using Alizarin red staining technique. The interaction between histone deacetylase 6 (HDAC6) and A-kinase anchoring protein 12 (AKAP12) was investigated through Co- immunoprecipitation.Results: CGRP treatment promoted rat bone marrow-derived macrophages (BMDMs) M2 polarization. CGRP facilitated osteogenic differentiation by enhancing M2 polarization of BMDMs. Mechanistically, CGRP promoted AKAP12 acetylation to activate the extracellular regulated protein kinases pathway by HDAC6 inhibition.Conclusion: CGRP promoted M2 polarization of rat BMDMs and facilitated osteogenic differentiation through the HDAC6/AKAP12/extracellular regulated protein kinases signaling pathway, thereby promoting bone healing.

目的:确定降钙素基因相关肽(CGRP)在骨愈合中的作用机制。材料与方法:用酶联免疫吸附法检测碱性磷酸酶(ALP)活性和炎症因子水平。使用茜素红染色技术评估成骨分化。通过共免疫沉淀法研究组蛋白去乙酰化酶6(HDAC6)和A-激酶锚定蛋白12(AKAP12)之间的相互作用。结果CGRP 可促进大鼠骨髓源性巨噬细胞(BMDMs)的 M2 极化。CGRP 通过增强 BMDMs 的 M2 极化促进成骨分化。从机制上讲,CGRP通过抑制HDAC6促进AKAP12乙酰化以激活细胞外调节蛋白激酶通路。结论CGRP能促进大鼠BMDMs的M2极化,并通过HDAC6/AKAP12/细胞外调节蛋白激酶信号通路促进成骨分化,从而促进骨愈合。
{"title":"CGRP promotes osteogenic differentiation by regulating macrophage M2 polarization through HDAC6/AKAP12 signaling pathway.","authors":"Wenjing Chen, Lin Ma, Wencai Sun, Wenlong Xiao, Hao Guo, Jiang Xiu, Xin Jiang","doi":"10.1080/17460751.2024.2370697","DOIUrl":"10.1080/17460751.2024.2370697","url":null,"abstract":"<p><p><b>Aim:</b> To determine the mechanism of Calcitonin gene-related peptide (CGRP) in bone healing.<b>Materials & methods:</b> Alkaline phosphatase (ALP) activity and inflammatory-factor levels were detected using ELISA. Osteogenic differentiation was assessed using Alizarin red staining technique. The interaction between histone deacetylase 6 (HDAC6) and A-kinase anchoring protein 12 (AKAP12) was investigated through Co- immunoprecipitation.<b>Results:</b> CGRP treatment promoted rat bone marrow-derived macrophages (BMDMs) M2 polarization. CGRP facilitated osteogenic differentiation by enhancing M2 polarization of BMDMs. Mechanistically, CGRP promoted AKAP12 acetylation to activate the extracellular regulated protein kinases pathway by HDAC6 inhibition.<b>Conclusion:</b> CGRP promoted M2 polarization of rat BMDMs and facilitated osteogenic differentiation through the HDAC6/AKAP12/extracellular regulated protein kinases signaling pathway, thereby promoting bone healing.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"379-391"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates from the field of stem cell research and regenerative medicine in April 2024. 2024 年 4 月干细胞研究和再生医学领域的行业动态。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI: 10.1080/17460751.2024.2365027
Dusko Ilic, Mirjana Liovic

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in April 2024.

2024 年 4 月干细胞研究和再生医学领域的最新进展,汇编自公开信息和非学术机构的新闻稿。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in April 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2365027","DOIUrl":"10.1080/17460751.2024.2365027","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in April 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"365-374"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates from the field of stem cell research and regenerative medicine in March 2024. 2024 年 3 月干细胞研究和再生医学领域的行业动态。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-05-28 DOI: 10.1080/17460751.2024.2353496
Dusko Ilic, Mirjana Liovic

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in March 2024.

2024 年 3 月干细胞研究和再生医学领域的最新进展,汇编自公开信息和非学术机构的新闻稿。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in March 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2353496","DOIUrl":"10.1080/17460751.2024.2353496","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in March 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"19 7-8","pages":"355-363"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduction of Activin A gives rise to comparable expression of key definitive endoderm and mature beta cell markers. 减少 Activin A 会导致关键的最终内胚层和成熟β细胞标志物的表达不相上下。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-01-19 DOI: 10.2217/rme-2023-0187
Aldyn Wildey, Stephen Harrington, Lisa Stehno-Bittel, Francis Karanu

Aim: Cell therapies for diabetes rely on differentiation of stem cells into insulin-producing cells, which is complex and expensive. Our goal was to evaluate production costs and test ways to reduce it. Methods: Cost of Goods (COGs) analysis for differentiation was completed and the effects of replacement or reduction of the most expensive item was tested using qRT-PCR, immunohistochemistry, flow cytometry along with glucose-stimulated insulin release. Results: Activin A (AA) was responsible for significant cost. Replacement with small molecules failed to form definitive endoderm (DE). Reducing AA by 50% did not negatively affect expression of beta cell markers. Conclusion: Reduction of AA concentration is feasible without adversely affecting DE and islet-like cell differentiation, leading to significant cost savings in manufacturing.

目的:治疗糖尿病的细胞疗法依赖于将干细胞分化为胰岛素分泌细胞,这既复杂又昂贵。我们的目标是评估生产成本,并测试降低成本的方法。方法:使用 qRT-PCR、免疫组织化学、流式细胞术和葡萄糖刺激胰岛素释放法测试替代或减少最昂贵项目的效果。结果显示活化素 A(AA)的成本很高。用小分子替代无法形成确定性内胚层(DE)。将 AA 减少 50%不会对β细胞标记物的表达产生负面影响。结论:降低 AA 浓度是可行的,不会对 DE 和类岛细胞分化产生不利影响,从而大大节约了生产成本。
{"title":"Reduction of Activin A gives rise to comparable expression of key definitive endoderm and mature beta cell markers.","authors":"Aldyn Wildey, Stephen Harrington, Lisa Stehno-Bittel, Francis Karanu","doi":"10.2217/rme-2023-0187","DOIUrl":"10.2217/rme-2023-0187","url":null,"abstract":"<p><p><b>Aim:</b> Cell therapies for diabetes rely on differentiation of stem cells into insulin-producing cells, which is complex and expensive. Our goal was to evaluate production costs and test ways to reduce it. <b>Methods:</b> Cost of Goods (COGs) analysis for differentiation was completed and the effects of replacement or reduction of the most expensive item was tested using qRT-PCR, immunohistochemistry, flow cytometry along with glucose-stimulated insulin release. <b>Results:</b> Activin A (AA) was responsible for significant cost. Replacement with small molecules failed to form definitive endoderm (DE). Reducing AA by 50% did not negatively affect expression of beta cell markers. <b>Conclusion:</b> Reduction of AA concentration is feasible without adversely affecting DE and islet-like cell differentiation, leading to significant cost savings in manufacturing.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"47-63"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient, parent and professional expert perspectives on personalized regenerative implants: a qualitative focus group study. 患者、家长和专业专家对个性化再生植入物的看法:焦点小组定性研究。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-09-02 DOI: 10.1080/17460751.2024.2386214
Manon van Daal, Anne-Floor J de Kanter, Roel Jh Custers, Elena Martínez-Sanz, Annelien L Bredenoord, Nienke de Graeff

Background: Perspectives of patients, parents and professional experts on personalized regenerative implants for regenerative medicine purposes are largely unknown.Method: To better understand these perspectives, we conducted four focus groups with professional experts of mixed European nationality (n = 8), Dutch patients with regular implants (n = 8), Dutch and Belgian (n = 5) and Spanish (n = 8) parents of children with cleft palate.Results: Two overarching themes were identified: 'patient-centered research and care' and 'ambivalent attitudes toward personalized regenerative implants'.Discussion: The results reveal that stakeholders should adopt a participatory rather than an impairment discourse and address the ambivalence among professional experts, patients and parents.Conclusion: Considering stakeholder perspectives facilitates ethical and responsible development and use of personalized regenerative implants.

背景:患者、家长和专业专家对用于再生医学目的的个性化再生植入物的看法大多不为人知:为了更好地了解这些观点,我们与欧洲混合国籍的专业专家(n = 8)、接受常规植入物的荷兰患者(n = 8)、荷兰和比利时(n = 5)以及西班牙(n = 8)腭裂患儿的父母进行了四次焦点小组讨论:结果:确定了两大主题:结果:确定了两个总体主题:"以患者为中心的研究和护理 "和 "对个性化再生植入体的矛盾态度":讨论:研究结果表明,利益相关者应采取参与性而非损害性的讨论方式,并解决专业专家、患者和家长的矛盾态度:结论:考虑利益相关者的观点有助于开发和使用个性化再生植入体,并使其符合道德规范和责任要求。
{"title":"Patient, parent and professional expert perspectives on personalized regenerative implants: a qualitative focus group study.","authors":"Manon van Daal, Anne-Floor J de Kanter, Roel Jh Custers, Elena Martínez-Sanz, Annelien L Bredenoord, Nienke de Graeff","doi":"10.1080/17460751.2024.2386214","DOIUrl":"10.1080/17460751.2024.2386214","url":null,"abstract":"<p><p><b>Background:</b> Perspectives of patients, parents and professional experts on personalized regenerative implants for regenerative medicine purposes are largely unknown.<b>Method:</b> To better understand these perspectives, we conducted four focus groups with professional experts of mixed European nationality (n = 8), Dutch patients with regular implants (n = 8), Dutch and Belgian (n = 5) and Spanish (n = 8) parents of children with cleft palate.<b>Results:</b> Two overarching themes were identified: 'patient-centered research and care' and 'ambivalent attitudes toward personalized regenerative implants'.<b>Discussion:</b> The results reveal that stakeholders should adopt a participatory rather than an impairment discourse and address the ambivalence among professional experts, patients and parents.<b>Conclusion:</b> Considering stakeholder perspectives facilitates ethical and responsible development and use of personalized regenerative implants.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"19 7-8","pages":"393-406"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of bone marrow derived mesenchymal stem cell extracellular vesicle injection for lumbar facet joint pain. 骨髓间充质干细胞细胞外囊注射治疗腰椎面关节疼痛的安全性。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-02-08 DOI: 10.2217/rme-2023-0110
James E Wilson, Bobbie A Today, Maria Salazar, Jonathann Kuo, John T Ransom, Amy L Lightner, Grace Chen, Anita Wong

Aim: A 3-month pilot study to evaluate the safety of injecting a bone marrow-derived mesenchymal stem cell extracellular vesicle advanced investigational product (IP) into the lumbar facet joint space as a treatment for chronic low back pain. Methods: 20 healthy adults were treated with IP injections (0.5 ml/joint) and evaluated by three functional assessments 1, 3, 7, 14, 30, 60 and 90 days later. Results: No adverse effects or complications occurred across the 3-month follow-up. There were no reports of worsening pain. After 3 months group average scores improved significantly (p < 0.0001) in the Severity Index (65.04%), Interference Index (72.09%) and Oswestry Disability Index (58.43%) assessments. Conclusion: IP injections were safe and associated with significant functional improvements.

目的:一项为期3个月的试验性研究,评估在腰椎面关节间隙注射骨髓间充质干细胞胞外囊高级研究产品(IP)治疗慢性腰痛的安全性。方法:对20名健康成年人进行IP注射(0.5毫升/关节)治疗,并在1、3、7、14、30、60和90天后进行三次功能评估。结果:3 个月的随访期间未出现不良反应或并发症。没有疼痛恶化的报告。3 个月后,治疗组的平均得分明显提高(p 结论:IP 注射是安全的,并与疼痛相关:IP 注射是安全的,并能显著改善功能。
{"title":"Safety of bone marrow derived mesenchymal stem cell extracellular vesicle injection for lumbar facet joint pain.","authors":"James E Wilson, Bobbie A Today, Maria Salazar, Jonathann Kuo, John T Ransom, Amy L Lightner, Grace Chen, Anita Wong","doi":"10.2217/rme-2023-0110","DOIUrl":"10.2217/rme-2023-0110","url":null,"abstract":"<p><p><b>Aim:</b> A 3-month pilot study to evaluate the safety of injecting a bone marrow-derived mesenchymal stem cell extracellular vesicle advanced investigational product (IP) into the lumbar facet joint space as a treatment for chronic low back pain. <b>Methods:</b> 20 healthy adults were treated with IP injections (0.5 ml/joint) and evaluated by three functional assessments 1, 3, 7, 14, 30, 60 and 90 days later. <b>Results:</b> No adverse effects or complications occurred across the 3-month follow-up. There were no reports of worsening pain. After 3 months group average scores improved significantly (p < 0.0001) in the Severity Index (65.04%), Interference Index (72.09%) and Oswestry Disability Index (58.43%) assessments. <b>Conclusion:</b> IP injections were safe and associated with significant functional improvements.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"19-26"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unconventional strategies for liver tissue engineering: plant, paper, silk and nanomaterial-based scaffolds. 肝脏组织工程的非常规策略:基于植物、纸张、丝绸和纳米材料的支架。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1080/17460751.2024.2378615
Sanyam Jain, Jai Gopal Sharma

The paper highlights how significant characteristics of liver can be modeled in tissue-engineered constructs using unconventional scaffolds. Hepatic lobular organization and metabolic zonation can be mimicked with decellularized plant structures with vasculature resembling a native-hepatic lobule vascular arrangement or silk blend scaffolds meticulously designed for guided cellular arrangement as hepatic patches or metabolic activities. The functionality of hepatocytes can be enhanced and maintained for long periods in naturally fibrous structures paving way for bioartificial liver development. The phase I enzymatic activity in hepatic models can be raised exploiting the microfibrillar structure of paper to allow cellular stacking creating hypoxic conditions to induce in vivo-like xenobiotic metabolism. Lastly, the paper introduces amalgamation of carbon-based nanomaterials into existing scaffolds in liver tissue engineering.

论文重点介绍了如何利用非常规支架在组织工程构建物中模拟肝脏的重要特征。肝小叶组织和新陈代谢分区可通过脱细胞植物结构进行模拟,该结构的脉管与原生肝小叶血管排列相似,或通过丝绸混合支架进行精心设计,以引导细胞排列为肝补片或新陈代谢活动。肝细胞的功能可在天然纤维结构中得到增强和长期保持,为生物人工肝的开发铺平了道路。利用纸张的微纤维结构,可以提高肝脏模型的 I 期酶活性,允许细胞堆叠,创造缺氧条件,诱导类似活体的异生物代谢。最后,论文介绍了在肝组织工程中将碳基纳米材料与现有支架的结合。
{"title":"Unconventional strategies for liver tissue engineering: plant, paper, silk and nanomaterial-based scaffolds.","authors":"Sanyam Jain, Jai Gopal Sharma","doi":"10.1080/17460751.2024.2378615","DOIUrl":"10.1080/17460751.2024.2378615","url":null,"abstract":"<p><p>The paper highlights how significant characteristics of liver can be modeled in tissue-engineered constructs using unconventional scaffolds. Hepatic lobular organization and metabolic zonation can be mimicked with decellularized plant structures with vasculature resembling a native-hepatic lobule vascular arrangement or silk blend scaffolds meticulously designed for guided cellular arrangement as hepatic patches or metabolic activities. The functionality of hepatocytes can be enhanced and maintained for long periods in naturally fibrous structures paving way for bioartificial liver development. The phase I enzymatic activity in hepatic models can be raised exploiting the microfibrillar structure of paper to allow cellular stacking creating hypoxic conditions to induce <i>in vivo</i>-like xenobiotic metabolism. Lastly, the paper introduces amalgamation of carbon-based nanomaterials into existing scaffolds in liver tissue engineering.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"421-437"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of CD45 in non-hematopoietic cells: implications in regenerative medicine and disease management. 非造血细胞中 CD45 的表达:对再生医学和疾病管理的影响。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-07-26 DOI: 10.1080/17460751.2024.2378627
Madhurima Das, Prajakta Teli, Anuradha Vaidya, Vaijayanti Kale

CD45 plays a crucial role in the regulation of hematopoiesis. However, a comprehensive understanding of its role in non-hematopoietic cells is lacking. Several tissue precursors express CD45, indicating its crucial role in tissue regeneration. These precursors would fall prey to the recent therapies involving CD45 as a target. CD45+ double-positive tumor cells contribute to cancer progression, but whether CD45 is involved in the process needs to be investigated. Recently, we showed that aging induces CD45 expression in mesenchymal stromal cells and affects their differentiation potential. In this review, we, for the first time, unravel the important implications of the expression of CD45 in non-hematopoietic cells and provide novel insights into its potential therapeutic target in regenerative medicine and disease management.

CD45 在调节造血过程中发挥着至关重要的作用。然而,人们对其在非造血细胞中的作用还缺乏全面的了解。一些组织前体表达 CD45,表明它在组织再生中起着关键作用。这些前体细胞会成为最近以 CD45 为靶点的疗法的牺牲品。CD45+ 双阳性肿瘤细胞有助于癌症进展,但 CD45 是否参与了这一过程还有待研究。最近,我们发现衰老会诱导间充质基质细胞中 CD45 的表达,并影响其分化潜能。在这篇综述中,我们首次揭示了 CD45 在非造血细胞中表达的重要意义,并对其在再生医学和疾病治疗中的潜在治疗靶点提供了新的见解。
{"title":"Expression of CD45 in non-hematopoietic cells: implications in regenerative medicine and disease management.","authors":"Madhurima Das, Prajakta Teli, Anuradha Vaidya, Vaijayanti Kale","doi":"10.1080/17460751.2024.2378627","DOIUrl":"10.1080/17460751.2024.2378627","url":null,"abstract":"<p><p>CD45 plays a crucial role in the regulation of hematopoiesis. However, a comprehensive understanding of its role in <i>non-hematopoietic</i> cells is lacking. Several tissue precursors express CD45, indicating its crucial role in tissue regeneration. These precursors would fall prey to the recent therapies involving CD45 as a target. CD45<sup>+</sup> double-positive tumor cells contribute to cancer progression, but whether CD45 is involved in the process needs to be investigated. Recently, we showed that aging induces CD45 expression in mesenchymal stromal cells and affects their differentiation potential. In this review, we, for the first time, unravel the important implications of the expression of CD45 in <i>non-hematopoietic</i> cells and provide novel insights into its potential therapeutic target in regenerative medicine and disease management.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"407-419"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the readiness of the Irish healthcare system to adopt advanced therapies: a scoping review protocol. 探索爱尔兰医疗系统采用先进疗法的准备情况:范围界定审查协议。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-07-16 DOI: 10.1080/17460751.2024.2368352
Isabella Devine, Clarice O'Brien, David Mockler, Cormac Kennedy, Gerry Hughes, Martina Hennessy

Aim: Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. However, ATMP adoption requires adjustments to current clinical practices and frameworks. This study investigates the readiness of the Irish healthcare system to adopt licensed ATMPs. Materials & methods: Scoping review, guided by the preferred reporting items for systematic reviews and meta-analyses - scoping review extension. A systematic search of English articles from 2013 to 2023 (published and grey literature) will be conducted.Results: Findings will be presented via narrative summary, graphical and tabular formats.Discussion: Review findings will be discussed in the context of recommendations that will inform national policy and strategy on the adoption of ATMPs in Ireland.

目的:先进治疗药物产品(ATMP)是基于基因、组织或细胞的人类用药。它们为治疗疾病和损伤提供了突破性的新机遇。然而,采用 ATMP 需要对当前的临床实践和框架进行调整。本研究调查了爱尔兰医疗系统采用获得许可的 ATMP 的准备情况。材料与方法:范围界定审查,以系统审查和荟萃分析的首选报告项目为指导--范围界定审查扩展。将对 2013 年至 2023 年的英文文章(已发表和灰色文献)进行系统检索。结果:研究结果将以叙述性摘要、图表和表格的形式呈现。讨论:将结合相关建议讨论综述结果,这些建议将为爱尔兰采用 ATMP 的国家政策和战略提供参考。
{"title":"Exploring the readiness of the Irish healthcare system to adopt advanced therapies: a scoping review protocol.","authors":"Isabella Devine, Clarice O'Brien, David Mockler, Cormac Kennedy, Gerry Hughes, Martina Hennessy","doi":"10.1080/17460751.2024.2368352","DOIUrl":"10.1080/17460751.2024.2368352","url":null,"abstract":"<p><p><b>Aim:</b> Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. However, ATMP adoption requires adjustments to current clinical practices and frameworks. This study investigates the readiness of the Irish healthcare system to adopt licensed ATMPs. <b>Materials & methods:</b> Scoping review, guided by the preferred reporting items for systematic reviews and meta-analyses - scoping review extension. A systematic search of English articles from 2013 to 2023 (published and grey literature) will be conducted.<b>Results:</b> Findings will be presented via narrative summary, graphical and tabular formats.<b>Discussion:</b> Review findings will be discussed in the context of recommendations that will inform national policy and strategy on the adoption of ATMPs in Ireland.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"439-444"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring stem cell therapies: an interview with Darius Widera. 探索干细胞疗法:专访达柳斯-维德拉。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-01-01 Epub Date: 2024-07-18 DOI: 10.1080/17460751.2024.2375104
Darius Widera
{"title":"Exploring stem cell therapies: an interview with Darius Widera.","authors":"Darius Widera","doi":"10.1080/17460751.2024.2375104","DOIUrl":"10.1080/17460751.2024.2375104","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"375-377"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Regenerative medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1